In our special Christmas episode, Mr. Reinhard Ernst (Wiesbaden) discusses the importance of access to abstract art in general and to abstract expressionism in painting in particular for people in Germany in 2026 youtu.be/HZPtOtj_058?...

The MARKUS@HOME editorial team wishes all colleagues a peaceful and blessed Christmas 2025. Thank you for your interest in our webinars. We look forward to seeing you again in 2026! youtu.be/P64PnU0WyZE?...

Short-Term DOAC vs. DAPT for Preventing Device Thrombosis Following LAA-Closure: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al. www.ahajournals.org/doi/10.1161/... The use of DOACs after LAAC failed to reduce DRT compared with DAPT, but it was associated with an improved safety profile.

It's that time again: Best of Cardiologie 2025 youtu.be/FAOH0tL2Cy8?... Watch now!

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes by Drs. Nicholls, D’Alessio et al. www.nejm.org/doi/full/10.... Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide.

Exercise and Kidney Health: Core Curriculum 2026 by Drs. Becerra, Mansour. www.ajkd.org/article/S027... This core curriculum reviews the physiology of exercise on kidney function and provides evidence-based strategies for patient counseling and risk reduction.

Update AF: DECAF & CABG-AF Gregory Marcus & Florian Herrmann youtu.be/48AQF8xaW-8?...

Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis by Drs. van Essen, Tromp et al. www.jacc.org/doi/10.1016/...

Tonight: Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier youtu.be/w8qCX2pRSxQ?... @bbikdeli.bsky.social

VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN by Drs. Fakhouri, Nester et al. www.nejm.org/doi/full/10.... Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.

Trends in CVE & Bleeding in Advanced CKD: SRR - Dr. M. Evans, Dr. A.-L. Faucon (Stockholm, Sweden) youtu.be/S2hbWPWkzcU?...

High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease by Drs. Bartholdy, Biering-Sørensen et al. www.jacc.org/doi/10.1016/... In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.

Extended DOAC Therapy in Provoked VTE - HI-PRO - Prof. Behnood Bikdeli, Prof. Romain Didier @bbikdeli.bsky.social youtu.be/e0Orc_Ps56U?...

Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD) by Drs. Johansen, Biering-Sørensen et al. www.thelancet.com/journals/lan... In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.

Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects by Drs. Herrmann, Mitchell et al. An International Cardio-Oncology Society Position Statement: jamanetwork.com/journals/jam...

Deferring Arterial Catheterization in Critically Ill Patients with Shock by Drs. Muller, Boulain et al. www.nejm.org/doi/pdf/10.1... Results for death from any cause at day 28 indicated that management without early arterial cath. insertion was noninferior to early cath. insertion.

Couldn't be there live? No problem, here are the highlights! Kongressupdate AHA / ASN 2025 youtu.be/pM956An3wJ8?... @asnkidney.bsky.social @ahascience.bsky.social

A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: LIBERATE-D by Drs. Liu, Hsu et al. jamanetwork.com/journals/jam... A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.

What an exciting weekend... So many new studies to discuss!

ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland youtu.be/-y_ma-kW61o?... Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio.bsky.social @eassociety.bsky.social.

Rituximab for Relapsing Nephrotic Syndrome in Adults by Drs. Isaka, Hiromura et al. jamanetwork.com/journals/jam... The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.

Short-Term Anticoagulation versus DAPT for Preventing Device Thrombosis Following LAAC: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al. www.ahajournals.org/doi/10.1161/... The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.

Stream it now! Our webinar in cooperation with NDT: IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan @ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social youtu.be/l0g9_lkW5_w?...

Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury The BICARICU-2 Randomized Clinical Trial by Drs. Jung, Jaber et al. jamanetwork.com/journals/jam... In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.

Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al. academic.oup.com/eurheartj/ar... Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.

Our experts explain: CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller youtu.be/RzupTGtHs8g?... They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al. www.nejm.org/doi/full/10.... The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.

Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) youtu.be/kK8N-5RkEfc?... Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.

Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al. academic.oup.com/eurheartj/ar... BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Herrington, Staplin et al. www.sciencedirect.com/science/arti... SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.

SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller youtu.be/9e-UFBnIyDI?... @ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social

The relationship between obesity and chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference by Drs. Furth, Rossing et al. www.kidney-international.org/article/S008...

Transthyretin amyloid cardiomyopathy: from cause to novel treatments by Drs. Fontana, Gillmore et al. academic.oup.com/eurheartj/ar...

Impfungen 25 / 26: Influenza, SARS-CoV-2, RSV, Pneumokokken - Prof. Dr. Klaus Stöhr, Prof. Dr. Barbara Gärtner youtu.be/V5P-eDvf9jI?...

Abnormal electrocardiogram findings in athletes by Drs. Finocchiaro, D’Ascenzi et al. A consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology! academic.oup.com/eurheartj/ar...

Atypical Hemotytic Uremic Syndrome (aHUS) - Prof. Fadi Fakhouri (Lausanne, Switzerland) youtu.be/k0UlfUh_PZU?... Prof. Fakhouri discusses pathophysiology, diagnosis, treatment and prognosis of atypical Hemolytic Uremic Syndrome (aHUS).

Anti-glomerular Basement Membrane Disease - Treatment Standard by Drs. McAdoo, Pusey et al. academic.oup.com/ndt/article/...

Primäre Hyperoxalurie - Prof. Dr. Bernd Hoppe (Bonn) Prof. Dr. Bernd Hoppe explains the pathophysiology, diagnostics, current and possible future therapies of primary hyperoxaluria. youtu.be/T18mxSSlG7g?...

KDIGO publishes its new guidelines on IgA Nephropathy (IgAN) / IgA Vasculitis (IgAV) kdigo.org/guidelines/i...

How to diagnose and treat superficial vein thrombosis (SuVT) by Drs. Piazza, Bikdeli et al. jamanetwork.com/journals/jam...

Tonight it's all about ADPKD! KDIGO Guidelines / ERA Genes & Kidney Working Group - Prof. Roser Torra, Prof. Roman-Ulrich Müller youtu.be/qjnYDsYbx0Q?... @rosertorra.bsky.social @muellerrom.bsky.social @dguerrot.bsky.social @gunnarheine.bsky.social @kronbichlerlab.bsky.social

"After all this time": More than five decades of Dr. Braunwald's research on Hypertrophic Cardiomyopathy summarized in a review paper by Dr. Braunwald www.nejm.org/doi/full/10....

Last days of summer...

It's Congress-Update time! Check out our new webinar "Post ESC 2025"! youtu.be/6C6lJWUHlc8?...

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension by Drs. Flack, Williams, et al. www.nejm.org/doi/full/10.... The addition of baxdrostat to background therapy resulted in a significantly lower seated systolic blood pressure at 12 weeks than placebo.

The ALONE-AF Randomized Clinical Trial by Drs. Kim, Joung, et al. jamanetwork.com/journals/jam... After AF ablation discontinuing OAC therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct OAC therapy.

An exciting weekend in Madrid for all cardiologists – ESC Congress 2025! What was your highlight?

Dialysate K+, GI K+ Binders & A Fib in HD - ADAPT - Prof. David Charytan (New York City, NY, USA) Prof. Dr. Charytan discusses how interventions into potassium homeostasis may affect the risk of atrial and ventricular arrhythmia, focussing upon his ADAPT study. youtu.be/IRIdrp1dk14?...

Effect of Intensive Blood Pressure Control on Stroke by Drs. Li & Li et al. www.jacc.org/doi/10.1016/... Compared with targeting <140 mmHg, targeting <120 mmHg halved the risk of hemorrhagic stroke and did not increase that of ischemic stroke.

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial by Drs. Turner, Holland et al. jamanetwork.com/journals/jam... In adult participants with complicated S aureus bacteremia, dalbavancin was not superior to standard therapy.